On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.’s (NYSE:ABBV) SKYRIZI (risankizumab-rzaa) for children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis.
A new 55 mg pre-filled syringe (PFS) has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available 150 mg PFS and Pen are approved for patients weighing 40 kg or greater.
Read Next
Trading Ideas
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst
